Accession Number:

ADA409785

Title:

Delivering DNA Vaccine by Transdermal Electroporation

Descriptive Note:

Annual rept. 1 Aug 2001-31 Jul 2002

Corporate Author:

HEALTH RESEARCH INC BUFFALO NY

Personal Author(s):

Report Date:

2002-08-01

Pagination or Media Count:

7.0

Abstract:

The HLA-A2 binding peptide, KIFGSLAFL, derived from breast cancer associated antigen HER-2neu, is to be delivered transdermally by electroporation to the dermal Langerhans cells LC, to stimulate the cytotoxic T-lymphocyte CTL response to breast cancer cells. We have extended, by using anionic lipids, the upper molecular weight limit of transdermal delivery of macromolecules by electroporation to 10,000. This enables the delivery of antigenic peptides but not minigenes. We measured the transdermal flux of antigenic peptides M.W.9,000 to be in the order of 1-10 mugcm2min, when 1 msec pulses of lOOV were applied to the skin at 1 Hz. The KlFGSLAFL peptide was delivered to HLA-A2Kb transgenic mice as a vaccine by transdermal electroporation. CTL response to delivery of the peptide vaccine KIFGSLAFL has so far been negative. We attribute the lack of response to either that the peptide delivered was insufficient, or that the adjuvants in transdermal electroporation were absent because of molecular weight limitation. Increase the amount of delivery, with or without co-injection of adjuvant, could overcome the problem.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE